Navigation Links
NanoBio Expands Drug Development Team for Its Anti-Infective Products
Date:9/25/2007

ANN ARBOR, Mich., Sept. 25 /PRNewswire/ -- NanoBio(R) Corporation, a biopharmaceutical company developing novel anti-infective topicals and mucosal vaccines to treat and prevent serious infections, today announced the addition of four new scientists to its drug development team.

Lyou-fu Ma, PharmD, Ph.D.; Susan Ciotti, Ph.D.; Robert L. Hagan, Ph.D. and Paula L. Robinson will guide NanoBio in developing and commercializing its novel topical anti-infectives and mucosal vaccines. NanoBio's lead products are topical anti-infective lotions to eradicate cold sores and nail fungus, while its mucosal vaccines are in various stages of preclinical and human testing.

Dr. Ma has assumed the position of senior vice president of development and regulatory affairs, while Dr. Ciotti is the new director of formulation research and development at NanoBio Corporation. Dr. Hagan will serve as the senior manager of supply chain and Ms. Robinson will assume the position of clinical project manager.

"Each of our new scientific team members has a rich and diverse background in the pharmaceutical industry that will ensure our company's success as we accelerate our drug development programs," said James R. Baker, Jr., NanoBio's founder and chief science officer. "Their experience in taking compounds from preclinical testing through development will be invaluable in testing and developing our current and future products."

NanoBio's clinical programs for herpes labialis (cold sores) and onychomycosis (nail fungus) treatment have already yielded promising results, with clinical trials having demonstrated unparalleled safety and tolerability, added Baker. The collective experience of Ma, Ciotti, Hagan and Robinson will further expand the company's rich pipeline of products, he said.

Dr. Ma has 17 years of experience in the pharmaceutical industry. Prior to joining NanoBio, she served as development team leader in the pain therapy area at Pfizer Global Researc
'/>"/>

SOURCE NanoBio Corporation
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. WARF expands license agreement with Advanced Cell Technology
2. Verizon expands broadband service in Wisconsin
3. Bandwidth provider expands in Milwaukee
4. Wisconsins biodiesel network expands
5. Quad/Graphics expands reach in western states
6. University of South Florida expands GE Healthcare relationship
7. Metavante expands healthcare payments division
8. Fiserv expands services to health plan market
9. Bone Care expands patent protection of core drug offering
10. SBC and AT&T merger expands global reach for Wisconsin businesses
11. Expetec expands IT staff services in Wisconsin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... May 21, 2013 Vital Imaging ... University of California, San Diego for a joint study ... Gravitic™ MRI (Magnetic Resonance Imaging) with that of a ... its continued pursuit of improved healthcare by combining cutting ... is an extremely valuable tool for evaluating pathological changes ...
(Date:5/21/2013)... CA (PRWEB) May 21, 2013 Clinovo's ... is an 8-week training program starting on June 11th, ... help clinical trial professionals reach the next step in ... Dentons Offices in Palo Alto, and streamed online. , ... of award-winning papers, Clinovo's new “CDISC Standards: Theory and ...
(Date:5/20/2013)... 20, 2013 Today, at the American Psychiatric ... , James McGough , M.D., M.S., ... Semel Institute for Neuroscience and Human Behavior and ... the University of California Los Angeles (UCLA), and director ... Psychopharmacology and ADHD at UCLA, presented the results of ...
(Date:5/20/2013)... ROCKVILLE , Md. and BALTIMORE ... Inc. (BHI), a regional private-public partnership focusing ... to early-stage funding in Central Maryland ... Aiyar, Ph.D., M.B.A., as the first Entrepreneur-in-Residence (EIR) ... (NIH) National Heart, Lung and Blood Institute ...
Breaking Biology Technology:Vital Imaging Makes Greater Commitment into MRI Research 2Vital Imaging Makes Greater Commitment into MRI Research 3Clinovo Launches TechTrainings on CDISC Standards 2Positive Results Reported for Phase I Clinical Trial at UCLA for the Treatment of ADHD in Children Using External Trigeminal Nerve Stimulation (eTNS) 2Positive Results Reported for Phase I Clinical Trial at UCLA for the Treatment of ADHD in Children Using External Trigeminal Nerve Stimulation (eTNS) 3Positive Results Reported for Phase I Clinical Trial at UCLA for the Treatment of ADHD in Children Using External Trigeminal Nerve Stimulation (eTNS) 4Positive Results Reported for Phase I Clinical Trial at UCLA for the Treatment of ADHD in Children Using External Trigeminal Nerve Stimulation (eTNS) 5BioHealth Innovation, Inc. Names Ram Aiyar as Entrepreneur-in-Residence to NIH National Heart, Lung and Blood Institute 2BioHealth Innovation, Inc. Names Ram Aiyar as Entrepreneur-in-Residence to NIH National Heart, Lung and Blood Institute 3BioHealth Innovation, Inc. Names Ram Aiyar as Entrepreneur-in-Residence to NIH National Heart, Lung and Blood Institute 4
... - iCo Therapeutics Inc. (TSX-V: ICO) is pleased to ... This financing provides the company with sufficient capital to ... 1 clinical trial. iCo-007 is targeting the treatment of ... the company with additional working capital. iCo,s partner Isis ...
... Inc. (Nasdaq: VRUS ), a clinical ... commercializing novel drugs to treat viral infections, reported ... quarter ended December 31, 2008. Financial Results ... quarters ended December 31, 2008 and December 31, ...
... 9 Celsis In Vitro Technologies (Celsis,IVT), a ... science,products and laboratory services company, and Wisconsin-based Promega ... ADME-Tox testing in primary,hepatocytes. Celsis IVT is ... with Promega,s bioluminescent ADME-Tox assays, including,the P450-Glo(TM) CYP ...
Cached Biology Technology:iCo Therapeutics Closes $1.3 Million Private Placement 2iCo Therapeutics Closes $1.3 Million Private Placement 3Pharmasset Reports Fiscal First Quarter 2009 Financial Results 2Pharmasset Reports Fiscal First Quarter 2009 Financial Results 3Pharmasset Reports Fiscal First Quarter 2009 Financial Results 4Pharmasset Reports Fiscal First Quarter 2009 Financial Results 5Pharmasset Reports Fiscal First Quarter 2009 Financial Results 6Pharmasset Reports Fiscal First Quarter 2009 Financial Results 7Pharmasset Reports Fiscal First Quarter 2009 Financial Results 8Celsis In Vitro Technologies and Promega to Offer Fast, Reliable Solutions for ADME-Tox Testing With Primary Hepatocytes 2Celsis In Vitro Technologies and Promega to Offer Fast, Reliable Solutions for ADME-Tox Testing With Primary Hepatocytes 3
(Date:5/21/2013)... of Michigan Water Center today awarded 12 research ... restoration and protection efforts. , The two-year grants ... including efforts to track the remediation of harmful ... control non-native weedy plant invasions; study chromosomal damage ... to restoration activities. , The grants were awarded ...
(Date:5/21/2013)... the past few decades, scientists have developed many devices ... metallic stents. While generally effective, each of these treatments ... A new study from MIT analyzes the potential usefulness ... angioplasty balloons and drug-releasing stents, but may pose fewer ... in the artery for only a brief period, during ...
(Date:5/20/2013)... are also commonly resistant to antimicrobial substances made ... in mBio , the online open-access journal ... colistin and host antimicrobials LL-37 and lysozyme, which ... mean that patients with life-threatening multi-drug resistant infections ... Colistin is a last-line drug for treating several ...
Breaking Biology News(10 mins):U-M Water Center awards $570K in Great Lakes restoration grants 2U-M Water Center awards $570K in Great Lakes restoration grants 3U-M Water Center awards $570K in Great Lakes restoration grants 4Evaluating a new way to open clogged arteries 2Evaluating a new way to open clogged arteries 3Resistance to last-line antibiotic makes bacteria resistant to immune system 2Resistance to last-line antibiotic makes bacteria resistant to immune system 3
... 2011Mary Ann Liebert, Inc., publishers ( http://www.liebertpub.com ) ... Technology , a highly innovative, bimonthly peer-reviewed journal ... the potential to significantly improve human health, well-being, ... innovative results, essential data, cutting-edge discoveries, thorough syntheses ...
... November 14, 2011 The possibility that functional, three-dimensional ... such as embryonic stem cells (ESCs) and induced pluripotent ... of stem cell research, but is also one of ... medicine. Developmental biology has played a central role in ...
... University Hospitals Case Medical Center researchers could still be ... not as they originally thought. LateTIME was a ... marrow that were believed to have the ability to ... the heart within two weeks of the attack. Results ...
Cached Biology News:New journal on disruptive science and technology launching in 2012 2Self-organized pituitary-like tissue from mouse ES cells 2Self-organized pituitary-like tissue from mouse ES cells 3Self-organized pituitary-like tissue from mouse ES cells 4Post heart attack recovery may not be aided by stem cell injections, but trial demonstrates promise 2
... for easy storage. Linkage: This CLS number is ... Cornings product number. If showing no availability yet, ... or contact customer service for assistance. ID clarifier: ... 55 cm 2 D H 100 ...
... Mixes are formulated for use in one-step ... Green. One-step QRT-PCR mixes offer a quick ... pipetting steps are minimised, making the protocol ... 2x ABsolute QRT-PCR Mix is supplied with ...
... wide variety of environmental and pathophysiological stressful ... of proteins known as heat shock proteins ... proteins (SRPs). The Hsp90 family of ... alpha and beta, Grp94, and Trap-1 (Hsp75). ...
... offers bespoke, cost-effective solutions for complex protein processing and ... and experience to help you develop a solution to ... , ... transfer all methodology to your ...
Biology Products: